Top > Search of International Patents > NUCLEIC ACID APTAMER

NUCLEIC ACID APTAMER

Foreign code F210010294
File No. (S2019-0245-N0)
Posted date Jan 28, 2021
Country WIPO
International application number 2020JP020119
International publication number WO 2020235635
Date of international filing May 21, 2020
Date of international publication Nov 26, 2020
Priority data
  • P2019-096035 (May 22, 2019) JP
Title NUCLEIC ACID APTAMER
Abstract A nucleic acid aptamer that is capable of forming a guanine quadruplex structure in the presence of a cation and has a cell membrane permeability, wherein the nucleic acid aptamer comprises first, second, third and fourth regions forming the guanine quadruplex structure and connection regions A, B and C positioned respectively between the first and second regions, between the second and third regions and between the third and fourth regions; the first region has the base sequence represented by SEQ ID NO: 1; the second, third and fourth regions each have the base sequence represented by SEQ ID NO: 2; and at least one region selected from the group consisting of the connection regions A, B and C is capable of specifically binding to a target molecule in the presence of a cation.
Outline of related art and contending technology BACKGROUND ART
In recent years, antibody pharmaceuticals have become highly aggressive as therapeutic agents for cancer, but in addition to the high drug value, the type of disease-associated protein that can be handled is a plateau, and the limitation of antibody pharmaceuticals has also been seen. Therefore, development of post-antibody pharmaceuticals having a maternal structure different from that of antibodies is strongly desired. DNA / RNA aptamers formed from single-stranded DNA or RNA and having high binding capacity and selectivity with respect to biomolecules containing proteins are inexpensive to synthesize and have low antigenicity. therefore, attention is focused on as target recognition molecules instead of antibodies. Previously approved aptamer drugs include pegaptanib (trade name "Macugen", U.S. approved 2004, and Japanese approved 2008), which are drugs for treating age-related macular degeneration (, for example, see Patent Document 1.
However, antibody pharmaceuticals and nucleic acid aptamer pharmaceuticals approved thus far cannot permeate through the cell membrane, and thus the target is limited to extracellular. Therefore, it is desirable to develop a molecular targeting drug that can permeate through the cell membrane while maintaining the high molecular recognition ability and binding ability of antibodies and nucleic acid aptamers.
Furthermore, as a method for introducing a protein such as an antibody into a cell, a method using uptake into a cell by fusion or mixing with a transmembrane peptide and a method for introducing into a cell by liposome or the like have been known, but it has not been possible to put it into practical use because it is difficult to aggregate a target molecule and introduce only a specific molecule into a cell.
Scope of claims (In Japanese)[請求項1]
 陽イオン存在下でグアニン四重鎖構造を形成し、細胞膜透過能を有する、核酸アプタマーであって、
 グアニン四重鎖構造を形成する第1領域、第2領域、第3領域及び第4領域と、
 前記第1領域、前記第2領域、前記第3領域及び前記第4領域のそれぞれの間に連結領域A、連結領域B及び連結領域Cと、を有し
 前記第1領域は配列番号1に示される塩基配列からなり、
 前記第2領域、前記第3領域及び前記第4領域はそれぞれ配列番号2に示される塩基配列からなり、
 前記連結領域A、前記連結領域B及び前記連結領域Cからなる群より選ばれる少なくとも1つの領域は、陽イオン存在下で標的分子への特異的な結合能を有する、核酸アプタマー。

[請求項2]
 前記陽イオンが特定の種類の陽イオンである、請求項1に記載の核酸アプタマー。

[請求項3]
 前記第4領域の下流に、3’末端付加配列を更に有し、
 前記3’末端付加配列は、配列番号3に示される塩基配列からなる、請求項1又は2に記載の核酸アプタマー。

[請求項4]
 配列番号4に示される塩基配列からなるポリヌクレオチドを含む、請求項1~3のいずれか一項に記載の核酸アプタマー。

[請求項5]
 配列番号5~7のいずれかに示される塩基配列からなるポリヌクレオチドを含む、請求項1~4のいずれか一項に記載の核酸アプタマー。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NIIGATA UNIVERSITY
  • Inventor
  • CHUMAN Yoshiro
  • KANEKO Atsushi
  • WATARI Miyu
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL ST SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close